Compare JMM & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | JMM | GRML |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.8M | 51.5M |
| IPO Year | N/A | 2022 |
| Metric | JMM | GRML |
|---|---|---|
| Price | $5.79 | $0.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.7K | ★ 3.6M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 5.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.67 | $0.27 |
| 52 Week High | $6.52 | $0.55 |
| Indicator | JMM | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 48.32 | 30.94 |
| Support Level | $5.77 | $0.27 |
| Resistance Level | $5.90 | $0.44 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 53.13 | 9.64 |
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.